Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 May 1;130(5):2189-2191.
doi: 10.1172/JCI136475.

Moving from transplant as a treatment to transplant as a cure

Sam Kant  1 , Daniel C Brennan  1   2
Affiliations
Comment

Moving from transplant as a treatment to transplant as a cure

Sam Kant et al. J Clin Invest. .

Abstract

Immunosuppression continues to be a necessary component of transplantation, despite its association with a multitude of adverse effects. Numerous efforts have been made to circumvent the need for immunosuppression by using various techniques to achieve donor hyporesponsiveness. In this issue of the JCI, Morath et al. take this endeavor forward. Prior to transplantation, the researchers infused recipients with donor-modified immune cells and achieved immunologic hyporesponsiveness. This successful phase I trial also provides a possible avenue for achieving transplantation without the requisite immunosuppression.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: DCB receives consulting and speaker fees from CareDx and Sanofi and royalties from UpToDate. CareDx has provided research support to the Johns Hopkins School of Medicine.

Figures

Figure 1
Figure 1. A brief history of time: tolerance from discovery to application.
Timeline detailing the evolution of understanding immunologic tolerance and subsequent efforts to achieve it. RAR, renal allograft recipient; SAR, skin allograft recipient.
See this image and copyright information in PMC

Comment on

  • Phase I trial of donor-derived modified immune cell infusion in kidney transplantation.
    Morath C, Schmitt A, Kleist C, Daniel V, Opelz G, Süsal C, Ibrahim E, Kälble F, Speer C, Nusshag C, Pego da Silva L, Sommerer C, Wang L, Ni M, Hückelhoven-Krauss A, Czock D, Merle U, Mehrabi A, Sander A, Hackbusch M, Eckert C, Waldherr R, Schnitzler P, Müller-Tidow C, Hoheisel JD, Mustafa SA, Alhamdani MS, Bauer AS, Reiser J, Zeier M, Schmitt M, Schaier M, Terness P. Morath C, et al. J Clin Invest. 2020 May 1;130(5):2364-2376. doi: 10.1172/JCI133595. J Clin Invest. 2020. PMID: 31990685 Free PMC article. Clinical Trial.

References

    1. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004;77(5):769–776. doi: 10.1097/01.TP.0000110408.83054.88. - DOI - PubMed
    1. Joosten SA, Sijpkens YW, van Kooten C, Paul LC. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int. 2005;68(1):1–13. doi: 10.1111/j.1523-1755.2005.00376.x. - DOI - PubMed
    1. Golgert WA, Appel GB, Hariharan S. Recurrent glomerulonephritis after renal transplantation: an unsolved problem. Clin J Am Soc Nephrol. 2008;3(3):800–807. doi: 10.2215/CJN.04050907. - DOI - PMC - PubMed
    1. Owen RD. Immunogenetic consequences of vascular anastomoses between twins. Science. 1945;102(2651):400–401. doi: 10.1126/science.102.2651.400. - DOI - PubMed
    1. Anderson D, Billingham RE, Lampkin GH, Medawar PB. The use of skin grafting to distinguish between monozygotic and dizygotic twins in cattle. Heredity. 1951;5(3):379–397. doi: 10.1038/hdy.1951.38. - DOI